<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00964353</url>
  </required_header>
  <id_info>
    <org_study_id>16738B</org_study_id>
    <nct_id>NCT00964353</nct_id>
  </id_info>
  <brief_title>Clinical and Economic Implications of Genetic Testing for Warfarin Management</brief_title>
  <official_title>The Hospital and Economics CERT: Project 1: The Clinical and Economic Implications of Genetic Testing for Warfarin Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agency for Healthcare Research and Quality (AHRQ)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore how knowing genes that individuals inherit from their
      parents can make warfarin dosing more safe and effective. This study is being done to
      determine whether providing doctors with data on the genes their patients inherited and
      warfarin dosing recommendations based on those genes affects the costs and outcomes of care
      and after hospitalization for patients from different ethnic/racial backgrounds, and how
      physicians use this information in decision making.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall goal of this project is to develop and assess the effectiveness and
      cost-effectiveness of strategies that use genetic testing in the management of
      anticoagulation among racially diverse hospitalized patients. The project has four specific
      aims.

      Aim 1: To contribute patients initiating therapy at the University of Chicago Medical Center
      (UCMC) and affiliated hospitals to a genetic registry of a racially diverse set of patients
      undergoing warfarin therapy.

      Aim 2: To perform a randomized trial to determine the efficacy, costs and cost-effectiveness
      of existing pharmacogenetic algorithms for the management of warfarin therapy among
      hospitalized patients of all races.

      Aim 3: To develop clinical pharmacogenetic algorithms for the management of warfarin therapy
      among hospitalized African American patients.

      Aim 4: To perform a randomized trial to determine and compare the efficacy, costs and
      cost-effectiveness of existing clinical and non-racially tailored pharmacogenetic algorithms
      to racially tailored pharmacogenetic algorithms for the management of warfarin therapy among
      hospitalized African American patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inpatient Length of Stay</measure>
    <time_frame>during hospital stay, up to 60 days</time_frame>
    <description>Inpatient length of stay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Supratherapeutic Dosing</measure>
    <time_frame>during hospital stay, up to 60 days</time_frame>
    <description>International Normalized Ratio</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">359</enrollment>
  <condition>Blood Coagulation Disorders</condition>
  <arm_group>
    <arm_group_label>Clinically Guided Cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Estimated Effective Warfarin dosing calculations are based on clinical data algorithms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pharmacogenetically Guided Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estimated Effective Warfarin dosing calculations are based on genetic and clinical data algorithms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Dose estimates will be suggested daily for initial dose given and up to 4 consecutive doses after initial dose.</description>
    <arm_group_label>Clinically Guided Cohort</arm_group_label>
    <arm_group_label>Pharmacogenetically Guided Cohort</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  warfarin-naive patients

          -  ages 18 and older

          -  are undergoing inpatient anticoagulation initiation with warfarin for diagnoses that
             necessitate anticoagulation

        Exclusion Criteria:

          -  patients who are not warfarin-naive

          -  17 years of age or younger
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David O Meltzer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 12, 2009</study_first_submitted>
  <study_first_submitted_qc>August 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2009</study_first_posted>
  <results_first_submitted>October 8, 2019</results_first_submitted>
  <results_first_submitted_qc>November 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 25, 2019</results_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coumadine</keyword>
  <keyword>genotype</keyword>
  <keyword>genes</keyword>
  <keyword>Warfarin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Patients were deleted from the study due to patient delay of surgery, baseline INR being too high, patient rescheduling or canceling surgery, no INR ordered, no admission to hospital.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Control group received warfarin based on a clinically based dosing strategy during the first 6 days of therapy.</description>
        </group>
        <group group_id="P2">
          <title>Experimental</title>
          <description>Experimental arm received warfarin based on a genotype based therapy during the first 6 days of therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Estimated Effective Warfarin dosing calculations are based on clinical data algorithms
Warfarin: Dose estimates will be suggested daily for initial dose given and up to 4 consecutive doses after initial dose.</description>
        </group>
        <group group_id="B2">
          <title>Experimental</title>
          <description>Estimated Effective Warfarin dosing calculations are based on genetic and clinical data algorithms.
Warfarin: Dose estimates will be suggested daily for initial dose given and up to 4 consecutive doses after initial dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="181"/>
            <count group_id="B2" value="178"/>
            <count group_id="B3" value="359"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Age categories are defined as 18-39, 40-60, 61-75, and 75 years and up.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>18-39 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>40-60 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
                <category>
                  <title>61-75 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>75 years or more</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="341"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="178"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Inpatient Length of Stay</title>
        <description>Inpatient length of stay</description>
        <time_frame>during hospital stay, up to 60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control group received warfarin based on a clinically based dosing strategy during the first 6 days of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Experimental</title>
            <description>Experimental arm received warfarin based on a genotype based therapy during the first 6 days of therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Inpatient Length of Stay</title>
          <description>Inpatient length of stay</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="7.0"/>
                    <measurement group_id="O2" value="7.2" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Supratherapeutic Dosing</title>
        <description>International Normalized Ratio</description>
        <time_frame>during hospital stay, up to 60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control group received warfarin based on a clinically based dosing strategy during the first 6 days of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Experimental</title>
            <description>Experimental arm received warfarin based on a genotype based therapy during the first 6 days of therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Supratherapeutic Dosing</title>
          <description>International Normalized Ratio</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.2"/>
                    <measurement group_id="O2" value="2.2" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Control group received warfarin based on a clinically based dosing strategy during the first 6 days of therapy.</description>
        </group>
        <group group_id="E2">
          <title>Experimental</title>
          <description>Experimental arm received warfarin based on a genotype based therapy during the first 6 days of therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>DVT or PE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="181"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr David Meltzer</name_or_title>
      <organization>University of Chicago</organization>
      <phone>773-702-0836</phone>
      <email>dmeltzer@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

